CDEK by Data4ThePeople
Sign in Sign up
← All drugs Report issue

fluorocholine

Small moleculeexperimentalImaging agent

18F-Fluorocholine is a fluorinated choline derivative and an oncologic PET tracer. — Wikipedia

Clinical trial activity

19 trials · 23 clinical orgs · 0 marketing orgs

Phase 1
1
Phase 2
11
Phase 3
11
Phase 4
1

Earliest trial started Jun 1, 2009 (NCT00928174)

Timeline

2000s

  1. Jan 1, 2009

    Earliest Phase 1 Sponsor(trial)

2010s

  1. Jan 1, 2014

    Earliest Phase 3 Sponsor(trial)

  2. Jan 1, 2016

    Earliest Phase 2 Sponsor(trial)

Indications

Approved for

Studied for

Mechanism of action

  • Unspecified targetRadiopharmaceutical

    radiopharmaceutical

Chemistry & pharmacology

Loading structure…

SMILES

C[N+](C)(CF)CCO
Mol. weight
122.16 g/mol
Lipinski Ro5
Pass
Rule of 3
Yes
Chirality
Achiral Molecule
Inorganic
No
Polymer
No
Imaging
18-fluoride

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • 18f-fch
  • 18f-fch
  • 18f-fch
  • 18f fluorocholine
  • 18f fluorocholine
  • 18f-fluorocholine
  • 18f-fluorocholine
  • 18f-fluorocholine
  • f18 fluorocholine
  • fluorocholine
  • fluorocholine
  • fluorocholine
  • n,n-dimethyl-n-(18f)fluoromethyl-2-hydroxyethylammonium

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT05891769Phase 2/Phase 3 (Phase 3)Jul 1, 2023Stanford University
NCT05622162Phase 3Nov 30, 2022Advice Pharma Group srl, ITEL Telecomunicazioni Srl
NCT04999215Phase 3Mar 1, 2022University of Montreal
NCT04965454Phase 2Jan 1, 2022National Cancer Institute (NCI), The Queen's Medical Center, University of Nottingham
NCT04895631Phase 3Jun 30, 2021University of California, San Francisco
NCT04150458Phase 3Jan 31, 2020McGill University
NCT03891914Phase 3May 1, 2019University of Bordeaux
NCT04102553Phase 3Mar 6, 2019ABX advanced biochemical compounds GmbH
NCT03623425Phase 3Feb 1, 2019Advanced Nuclear Medicine Ingredients, University of Lorraine
NCT04340765N/AFeb 1, 2018Hualien Tzu Chi General Hospital, Tzu Chi University
NCT03764007Phase 2/Phase 3 (Phase 3)Sep 30, 2016University of California, San Francisco
NCT02849171N/AJul 1, 2016Cornell University
NCT03555487Phase 3May 5, 2015National Taiwan University
NCT02121600N/ASep 30, 2014Ontario Institute for Cancer Research, University of Western Ontario
NCT02074202Phase 3Feb 1, 2014National Taiwan University
NCT01993160N/ADec 1, 2013Prostate Cancer Canada Network, University of Toronto
NCT01769950N/AJan 31, 2013Bangalore Institute of Oncology
NCT01956409Phase 4Sep 1, 2012National Taiwan University
NCT00928174Phase 1/Phase 2 (Phase 2)Jun 1, 2009National Institutes of Health (NIH), The Queen's Medical Center, University of Nottingham
Showing 19 of 19 trials
Page 1 / 1

Organizations

Research & Development (23)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
National Taiwan UniversityAcademic/Hospital3322012
The Queen's Medical CenterAcademic/Hospital2012009
University of California, San FranciscoAcademic/Hospital2212016
University of NottinghamAcademic/Hospital2212009
ABX advanced biochemical compounds GmbHFor profit1112019
Advanced Nuclear Medicine IngredientsFor profit1012019
Advice Pharma Group srlFor profit1012022
Bangalore Institute of OncologyAcademic/Hospital1112013
Cornell UniversityAcademic/Hospital1112016
Hualien Tzu Chi General HospitalAcademic/Hospital1012018
ITEL Telecomunicazioni SrlFor profit1112022
McGill UniversityAcademic/Hospital1112020
National Cancer Institute (NCI)Government1012022
National Institutes of Health (NIH)Government1012009
Ontario Institute for Cancer ResearchAcademic/Hospital1012014
Prostate Cancer Canada NetworkAcademic/Hospital1012013
Stanford UniversityAcademic/Hospital1112023
Tzu Chi UniversityAcademic/Hospital1112018
University of BordeauxAcademic/Hospital1112019
University of LorraineAcademic/Hospital1112019
23 organizations
Page 1 / 2